Immix Biopharma (IMMX) Stock Forecast: StockMap's 2-Week Call

IMMX stock forecast: StockMap's model leans Underperform on Immix Biopharma for the two weeks after the Nov 19 close, toward IMMX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Too few two-week windows graded to judge yet.

Immix Biopharma last closed at $7.04, -0.98% on the session.

Against the IVW growth benchmark the position is +1.35% over the forecast window.

Immix Biopharma's market cap is $590.06M as of November 19, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -24 (too close to call).

Where IMMX sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

8 daily calls for IMMX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Immix Biopharma in the 20th percentile on return on equity, where 100 is best.

Immix Biopharma is classified under Health Care / Biotechnology.

StockMap tracks Immix Biopharma as the 161st largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Immix Biopharma ranks 187th of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Immix Biopharma (IMMX) — StockMap 2-week forecast & tracked accuracy